Silent Shortfalls That Hit New GLP-1 Users

More than one in five adults prescribed a GLP-1 receptor agonist will develop a measurable nutritional deficiency within their first year of treatment — and most of them will never know it, because no standard of care currently requires anyone to look.

Key Points

Large-scale real-world data on over 400,000 GLP-1 users shows 12.7% developed nutritional deficiencies within six months and 22.4% within twelve months — with vitamin D the most common, affecting nearly 14% of users by the one-year mark.
The deficits extend well beyond vitamin D: iron depletion, B12 insufficiency, low calcium, magnesium, potassium, and inadequate protein intake are all documented, with GLP-1 users showing ferritin levels 26–30% lower than comparable patients on other diabetes medications.
The mechanism is primarily dietary — appetite suppression so profound that even patients eating carefully cannot meet micronutrient thresholds at the caloric levels these drugs impose — compounded by GLP-1-induced changes in gastric motility that may impair absorption of certain nutrients.
No consensus clinical guidelines currently mandate micronutrient blood testing for GLP-1 patients, and many patients obtain these medications without the dietitian involvement that experts now consider essential.

The Scale of the Problem, Quantified

The evidence establishing this risk is no longer preliminary. A 2025 study published in Obesity Pillars examined insurance claims data for 461,382 adults newly prescribed GLP-1 receptor agonists between 2017 and 2021 — critically, none of whom had any prior diagnosis of nutritional deficiency. Within six months, 12.7% had received a new deficiency diagnosis. Within twelve months, that figure climbed to 22.4%. A systematic review following PRISMA-ScR and SANRA guidance, encompassing six studies and 480,825 adults, confirmed the trajectory: vitamin D deficiency incidence reached 7.5% at six months and 13.6% at twelve months, making it the single most common nutritional abnormality in this population.

These are not small, convenience-sample studies susceptible to selection bias. They are claims-data analyses at a scale that captures real prescribing patterns across diverse clinical settings. The consistency between independent datasets — different methodologies, different populations, arriving at nearly identical incidence rates — substantially strengthens the signal. The researchers behind the Obesity Pillars study were explicit: nutritional deficiencies should be considered “a common consequence” of GLP-1 therapy, not a rare complication.

Why Appetite Suppression Creates a Hidden Nutritional Trap

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and their predecessors — work by mimicking the glucagon-like peptide-1 hormone, which signals satiety to the brain and slows gastric emptying. The result is a dramatic reduction in appetite and food intake, often by 30–40% from baseline. That is precisely the mechanism that produces weight loss. It is also the mechanism that produces nutritional depletion.

At 800 to 1,200 calories per day — the range many GLP-1 users settle into without conscious restriction — meeting recommended daily allowances for micronutrients becomes mathematically difficult even with careful food selection. A study using three-day food records for 69 GLP-1 users found that 72% consumed less than recommended calcium, 64% fell short on iron, and only 1.4% met vitamin D recommendations. A separate Frontiers in Nutrition analysis documented consistent shortfalls in vitamin D, magnesium, potassium, choline, and iron across the user population. Calcium and fiber were also chronically under-consumed. The problem is not that GLP-1 users are eating poorly by conventional standards; it is that the volume of food required to deliver adequate micronutrients is simply incompatible with the suppressed appetite these drugs produce.

Gastric motility adds a second layer of risk. GLP-1 agonists slow the movement of food through the stomach and small intestine — a feature that moderates post-meal glucose spikes but that may also impair the absorption of nutrients like vitamin B12, which depends on adequate contact time with intrinsic factor in the stomach. Dr. Jen Ashton, double board-certified in obesity medicine and OBGYN with a master’s in human nutrition, draws a direct parallel to bariatric surgery patients, who face analogous absorption challenges and consequently receive lifelong micronutrient monitoring as standard care — a protocol not yet routine for GLP-1 users despite the drugs now being taken by an estimated 15 million Americans.

The Specific Nutrients at Risk, and Why Each Matters

Vitamin D dominates the deficiency data, but the spectrum of depletion is considerably broader. Iron depletion is the second most consequential finding: GLP-1 users show ferritin levels 26–30% lower than patients on SGLT2 inhibitors — a class of diabetes medications used as a comparator — indicating a systematic pattern of iron loss rather than individual variation. Women of reproductive age face compounded risk, since menstrual blood loss creates a baseline demand that reduced dietary iron cannot meet. The clinical consequences range from fatigue and impaired immune function to frank anemia and, in severe cases, koilonychia — the spoon-shaped nail deformity that signals chronic iron starvation.

Vitamin B12 deficiency is particularly insidious because its neurological consequences — peripheral neuropathy, cognitive changes, fatigue — emerge slowly, often after years of subclinical depletion, and can be irreversible if left untreated. Board-certified dermatologist Dr. Dray notes that B12 deficiency manifests in skin and mucosal changes that most clinicians and patients fail to recognize: hyperpigmentation in skin creases, premature graying, atrophic glossitis (a smooth, shiny tongue with red linear grooves), and angular cheilitis at the corners of the mouth. These are not cosmetic curiosities — they are early-warning signals of a deficiency that, if uncorrected, progresses to neurological damage.

Vitamin D’s consequences extend beyond bone health, though bone is where the compounding effect is most dangerous. Vitamin D works in concert with calcium and magnesium to maintain skeletal density; when all three are simultaneously under-consumed — which the dietary data suggests is common in GLP-1 users — the pathway toward accelerated bone loss opens. This is especially consequential for postmenopausal women and older men already operating with reduced bone density reserves. Emerging research also suggests that baseline vitamin D status may itself influence GLP-1 treatment outcomes: a 2026 Frontiers in Nutrition study found that higher baseline 25-hydroxyvitamin D levels were associated with better glycemic and weight-loss responses to GLP-1 therapy.

Muscle Loss: The Deficiency That Compounds the Deficiencies

Protein insufficiency deserves separate attention because its consequences interact with every other nutritional deficit. Up to 40% of weight lost on GLP-1 medications can be lean muscle mass rather than fat — a ratio that worsens with inadequate protein intake and physical inactivity. Sarcopenia, the clinical term for pathological muscle loss, was diagnosed in 3% of GLP-1 users in the Obesity Pillars dataset, though researchers and clinicians widely acknowledge this figure underestimates true prevalence, since sarcopenia requires specific diagnostic criteria rarely applied in routine care.

Muscle loss matters nutritionally because skeletal muscle is a metabolic reservoir — it stores glycogen, supports insulin sensitivity, and maintains the resting metabolic rate that determines long-term weight management. A patient who loses significant muscle mass during GLP-1 therapy may achieve striking short-term weight loss while simultaneously degrading the metabolic infrastructure that would sustain that loss. Registered dietitian Anna Rice Dorff, who has used GLP-1 medications for three years and works clinically with this population, recommends a protein target of 1.2 to 1.5 grams per kilogram of body weight daily, combined with resistance training — a combination the appetite suppression characteristic of these drugs makes difficult to achieve without deliberate, structured effort.

The Monitoring Gap: Why Deficiencies Go Undetected

The most troubling finding in this literature is not the deficiency rates themselves — it is the systematic failure to detect them. Current clinical guidelines, including the nutritional and lifestyle supportive care recommendations published in Obesity Pillars, advise personalized dietary counseling and dietitian involvement but do not mandate blood testing for micronutrient levels. In practice, this means that vitamin D, ferritin, B12, folate, and zinc are measured only when a clinician thinks to order them — which, in busy primary care settings, is rarely at the initiation of a new medication.

The data confirms the consequence: patients who had a dietitian visit within the first six months of GLP-1 therapy were significantly more likely to have deficiencies identified and addressed — not because the dietitian prevented deficiencies, but because dietitian involvement created a pathway for detection that otherwise did not exist. Researchers at UCL and the University of Cambridge, reviewing the available evidence on nutritional support for GLP-1 users, identified only twelve studies that examined nutrition and diet alongside semaglutide or tirzepatide treatment — a striking gap given the tens of millions of prescriptions now written annually. Dr. Dray cautions that a substantial proportion of patients obtain these medications without comprehensive medical supervision at all, through telehealth platforms or compounding pharmacies, further widening the monitoring gap.

Standard multivitamins do not close this gap. As noted in Psychology Today’s review of the evidence, off-the-shelf multivitamins typically contain inadequate doses of calcium, vitamin D, and potassium for the specific demands of GLP-1 users — whose requirements are shaped not just by reduced intake but by the altered absorption kinetics these drugs produce. A randomized controlled trial, registered as NCT07234916, is currently underway to measure the impact of multivitamin supplementation on serum levels of vitamin B12, vitamin D, and ferritin after twelve months of GLP-1 treatment — the kind of prospective, controlled evidence that will eventually sharpen supplementation guidance. Until those results are available, the expert consensus points toward individualized assessment: baseline labs before initiating therapy, followed by monitoring at six and twelve months, with panels that include 25-hydroxyvitamin D, serum ferritin, B12, folate, zinc, and a comprehensive metabolic panel.

What the Evidence Requires of Prescribers and Patients

The causality question deserves honest acknowledgment. All of the major studies establishing these deficiency rates are observational — they document associations between GLP-1 use and nutrient depletion, but cannot definitively rule out the contribution of pre-existing obesity-related deficiencies that were present before treatment began. People with obesity are already at elevated baseline risk for vitamin D insufficiency, iron depletion, and B12 inadequacy, due to sequestration of fat-soluble vitamins in adipose tissue, chronic low-grade inflammation, and dietary patterns that often preceded the prescription by years. The honest interpretation is that GLP-1 therapy likely exacerbates pre-existing vulnerabilities rather than creating deficiencies from scratch in previously replete individuals — a distinction that matters mechanistically but changes the clinical implication not at all. Whether the deficiency is new or worsened, it requires detection and correction.

The practical framework that emerges from this evidence is straightforward, even if its implementation requires systemic change. Prescribers should treat GLP-1 initiation the way bariatric surgeons treat pre-operative evaluation: with baseline micronutrient labs, a referral to a registered dietitian, and a monitoring schedule built into the treatment plan rather than left to the patient’s initiative. Patients should understand that the appetite suppression that makes these drugs effective is the same mechanism that creates nutritional risk — and that hair thinning, fatigue, brittle nails, and muscle weakness are not inevitable side effects to be tolerated but signals to be investigated. The drugs are genuinely effective and, for the populations they were designed to treat, genuinely important. The nutritional cost of that effectiveness is now quantified, documented at population scale, and eminently manageable — provided anyone is paying attention.